ADC Therapeutics
ADCT
49 hedge funds and large institutions have $501M invested in ADC Therapeutics in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 17 increasing their positions, 11 reducing their positions, and 10 closing their positions.
177% more call options, than puts
Call options by funds: $527K | Put options by funds: $190K
55% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 11
0.38% more ownership
Funds ownership: 44.05% → 44.43% (+0.38%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
11% less funds holding
Funds holding: 55 → 49 (-6)
27% less capital invested
Capital invested by funds: $683M → $501M (-$181M)
60% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCMC
Matrix Capital Management Company
Portsmouth,
New Hampshire
|
+$6.35M |
| 2 |
JP Morgan Chase
New York
|
+$3.49M |
| 3 |
Walleye Capital
New York
|
+$3.22M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$2.37M |
| 5 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
+$1.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$6.17M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$4.9M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$1.48M |
| 4 |
Millennium Management
New York
|
-$815K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$411K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
UBS Group
Zurich,
Switzerland
| – | -$49K | -2,426 | Closed |
|
52
Lazard Asset Management
New York
| – | -$37K | -1,863 | Closed |
|
|
DFCM
53
Dark Forest Capital Management
San Juan,
Puerto Rico
| – | -$8K | -387 | Closed |
|
54
Group One Trading
Chicago,
Illinois
| – | -$1.59K | -100 | Closed |
|
55
Simplex Trading
Chicago,
Illinois
| – | -$1.41K | -89 | Closed |
|
|
TFA
56
Toth Financial Advisory
Leesburg,
Virginia
| – | -$1K | -70 | Closed |
|
57
Citigroup
New York
| – | +$16 | +1 | +3% |
|
ADCT Hedge Fund Activity: Q1 2022 in Review
49 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in ADC Therapeutics (ADCT) for Q1 2022, worth a combined $501M — down 27% from $683M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ADCT and 4 opened new positions — a net loss of 6 holders — while 11 trimmed existing stakes and 17 added.
The largest buyer was Matrix Capital Management Company, opening a new position worth an estimated $6.35M. The largest seller was T. Rowe Price Associates, cutting an estimated $6.17M.
- 49 institutional investors held ADC Therapeutics (ADCT) as of Q1 2022, down from 55 in Q4 2021.
- Funds reported $501M of ADC Therapeutics stock for Q1 2022, down 27% quarter-over-quarter.
- 4 funds opened new ADC Therapeutics positions in Q1 2022 and 10 closed out, a net change of -6 holders.
- The largest ADC Therapeutics buyer in Q1 2022 was Matrix Capital Management Company, an estimated $6.35M added.
- The largest ADC Therapeutics seller in Q1 2022 was T. Rowe Price Associates, an estimated $6.17M sold.
Based on aggregated 13F filings for Q1 2022.